Skip to content

A new ophthalmic company – KalVista Pharmaceuticals – raises £8M to fund DME therapies

A new UK-based ophthalmology company – KalVista Pharmaceuticals – has announced the completion of an £8 million Series A funding round led by Novo A/S (Novo Nordisk) and SV Life Sciences, a life science venture capital investment firm. The new company, founded by Dr. Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School and Dr. Edward P. Feener, Associate Professor of Medicine, Harvard Medical School, will be supported by Mr. Andrew Crockett, CEO and will initially focus on the development of novel small molecule inhibitors of plasma kallikrein for the treatment of diabetic macular edema (DME).